Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1994-5-17
|
| pubmed:abstractText |
The pS2 protein was first detected in the oestrogen-dependent breast cancer cell line MCF-7. It may have prognostic value for primary breast cancer, and could be used to predict clinical responsiveness to endocrine therapy. In a retrospective study, the concentrations of pS2 protein were determined in 434 cytosol specimens using an immunoradiometric assay. The median values (4, 6 and 3 ng/mg protein) and the third quartiles (27, 26 and 29 ng/mg) in benign breast tumours (n = 17), and in primary (n = 325) and recurrent (n = 37) breast carcinomas were of the same order of magnitude. In primary breast cancer, high pS2 values (> 26 ng/mg) correlated significantly with a positive oestrogen receptor (ER) status and a high grade of tumour differentiation (P = 0.01). As many as 85% of the pS2 positive tumours were ER positive. A marginally significant correlation (P = 0.06) was also found between pS2 status and the quantitative expression of the ER. However, the pS2 values in ER positive endometrial carcinomas (n = 12) as well as in other benign and malignant genital tumours (n = 43) were more than 30 times lower than those measured in breast tumours. The results reveal a close association between pS2 protein and ER status which appears to be limited to breast cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Estrogens,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/TFF1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0932-0067
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
253
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
183-92
|
| pubmed:dateRevised |
2005-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8161252-Biopsy,
pubmed-meshheading:8161252-Breast Neoplasms,
pubmed-meshheading:8161252-Estrogens,
pubmed-meshheading:8161252-Female,
pubmed-meshheading:8161252-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:8161252-Genital Neoplasms, Female,
pubmed-meshheading:8161252-Humans,
pubmed-meshheading:8161252-Middle Aged,
pubmed-meshheading:8161252-Neoplasm Proteins,
pubmed-meshheading:8161252-Neoplasm Recurrence, Local,
pubmed-meshheading:8161252-Neoplasm Staging,
pubmed-meshheading:8161252-Prognosis,
pubmed-meshheading:8161252-Proteins,
pubmed-meshheading:8161252-Receptors, Estrogen,
pubmed-meshheading:8161252-Retrospective Studies,
pubmed-meshheading:8161252-Specimen Handling,
pubmed-meshheading:8161252-Survival Rate,
pubmed-meshheading:8161252-Tumor Suppressor Proteins
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Expression of pS2 protein in breast cancer.
|
| pubmed:affiliation |
Department of Obstetrics and Gynecology, University of Köln, Germany.
|
| pubmed:publicationType |
Journal Article
|